TrialJournal of Crohn's & colitis2026

Corticosteroid-sparing effects of risankizumab versus ustekinumab in patients with moderately to severely active Crohn's disease: post hoc results from the phase 3b SEQUENCE trial.

Tim Raine et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.